DD140503A5 - Diagnostisches verfahren - Google Patents

Diagnostisches verfahren Download PDF

Info

Publication number: DD140503A5
Authority: DD; German Democratic Republic
Prior art keywords: lymphocytes; poly; incubation; synthetic peptide; electric field
Prior art date: 1977-11-11

Application number

DD78208922A

Other languages

German (de)

English (en)

Inventor

Hartwig W Bauer

Wolfgang Ax

Original Assignee

Behringwerke Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1977-11-11

Filing date

1978-11-07

Publication date

1980-03-05

1978-11-07 Application filed by Behringwerke Ag filed Critical Behringwerke Ag

1980-03-05 Publication of DD140503A5 publication Critical patent/DD140503A5/de

Links

238000002405 diagnostic procedure Methods 0.000 title claims abstract description 6
210000004698 lymphocyte Anatomy 0.000 claims abstract description 21
108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 17
230000005684 electric field Effects 0.000 claims abstract description 12
230000005012 migration Effects 0.000 claims abstract description 8
238000013508 migration Methods 0.000 claims abstract description 8
238000000338 in vitro Methods 0.000 claims abstract description 5
239000002245 particle Substances 0.000 claims description 24
238000011534 incubation Methods 0.000 claims description 16
238000000034 method Methods 0.000 claims description 12
239000006228 supernatant Substances 0.000 claims description 10
239000000203 mixture Substances 0.000 claims description 8
102000004196 processed proteins & peptides Human genes 0.000 claims description 6
239000004472 Lysine Substances 0.000 claims description 5
229920001184 polypeptide Polymers 0.000 claims description 4
229960003104 ornithine Drugs 0.000 claims description 3
239000004475 Arginine Substances 0.000 claims description 2
AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 claims description 2
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 2
AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 claims description 2
UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 claims description 2
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 2
239000006185 dispersion Substances 0.000 claims description 2
229920000724 poly(L-arginine) polymer Polymers 0.000 claims description 2
239000002609 medium Substances 0.000 description 8
210000003743 erythrocyte Anatomy 0.000 description 5
239000000126 substance Substances 0.000 description 5
239000002253 acid Substances 0.000 description 4
239000000427 antigen Substances 0.000 description 4
102000036639 antigens Human genes 0.000 description 4
108091007433 antigens Proteins 0.000 description 4
229960003646 lysine Drugs 0.000 description 4
239000000243 solution Substances 0.000 description 4
206010028980 Neoplasm Diseases 0.000 description 3
210000004027 cell Anatomy 0.000 description 3
239000006285 cell suspension Substances 0.000 description 3
230000008859 change Effects 0.000 description 3
201000010099 disease Diseases 0.000 description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
238000001962 electrophoresis Methods 0.000 description 3
230000003211 malignant effect Effects 0.000 description 3
238000005259 measurement Methods 0.000 description 3
229920000729 poly(L-lysine) polymer Polymers 0.000 description 3
150000003839 salts Chemical class 0.000 description 3
239000000725 suspension Substances 0.000 description 3
YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
101710093543 Probable non-specific lipid-transfer protein Proteins 0.000 description 2
AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000008280 blood Substances 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
238000003745 diagnosis Methods 0.000 description 2
OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
229960002897 heparin Drugs 0.000 description 2
229920000669 heparin Polymers 0.000 description 2
239000001648 tannin Substances 0.000 description 2
235000018553 tannin Nutrition 0.000 description 2
229920001864 tannin Polymers 0.000 description 2
WCUHRFPGDJBHAQ-AYLNUICDSA-N (2s)-2-amino-5-[[(2r)-1-(carboxymethylamino)-1-oxo-3-sulfanylpropan-2-yl]amino]-5-oxopentanoic acid;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O WCUHRFPGDJBHAQ-AYLNUICDSA-N 0.000 description 1
WXHLLJAMBQLULT-UHFFFAOYSA-N 2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl]amino]-n-(2-methyl-6-sulfanylphenyl)-1,3-thiazole-5-carboxamide;hydrate Chemical compound O.C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1S WXHLLJAMBQLULT-UHFFFAOYSA-N 0.000 description 1
239000001763 2-hydroxyethyl(trimethyl)azanium Substances 0.000 description 1
DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
235000019743 Choline chloride Nutrition 0.000 description 1
AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
BRLQWZUYTZBJKN-UHFFFAOYSA-N Epichlorohydrin Chemical compound ClCC1CO1 BRLQWZUYTZBJKN-UHFFFAOYSA-N 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
239000012981 Hank's balanced salt solution Substances 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
229930064664 L-arginine Natural products 0.000 description 1
235000014852 L-arginine Nutrition 0.000 description 1
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
229930182844 L-isoleucine Natural products 0.000 description 1
235000019454 L-leucine Nutrition 0.000 description 1
239000004395 L-leucine Substances 0.000 description 1
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
102000008072 Lymphokines Human genes 0.000 description 1
108010074338 Lymphokines Proteins 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
239000004473 Threonine Substances 0.000 description 1
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
229930003270 Vitamin B Natural products 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
229940024606 amino acid Drugs 0.000 description 1
235000001014 amino acid Nutrition 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
230000001455 anti-clotting effect Effects 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
230000000890 antigenic effect Effects 0.000 description 1
238000013459 approach Methods 0.000 description 1
235000009697 arginine Nutrition 0.000 description 1
229960001230 asparagine Drugs 0.000 description 1
235000009582 asparagine Nutrition 0.000 description 1
235000003704 aspartic acid Nutrition 0.000 description 1
239000011324 bead Substances 0.000 description 1
230000008901 benefit Effects 0.000 description 1
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
229960002685 biotin Drugs 0.000 description 1
235000020958 biotin Nutrition 0.000 description 1
239000011616 biotin Substances 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
230000010261 cell growth Effects 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
229960003178 choline chloride Drugs 0.000 description 1
SGMZJAMFUVOLNK-UHFFFAOYSA-M choline chloride Chemical compound [Cl-].C[N+](C)(C)CCO SGMZJAMFUVOLNK-UHFFFAOYSA-M 0.000 description 1
229920001577 copolymer Polymers 0.000 description 1
229960003067 cystine Drugs 0.000 description 1
238000001514 detection method Methods 0.000 description 1
230000000694 effects Effects 0.000 description 1
230000001712 encephalitogenic effect Effects 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
229960000304 folic acid Drugs 0.000 description 1
235000019152 folic acid Nutrition 0.000 description 1
239000011724 folic acid Substances 0.000 description 1
239000012458 free base Substances 0.000 description 1
239000011521 glass Substances 0.000 description 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Natural products OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
239000008241 heterogeneous mixture Substances 0.000 description 1
239000008240 homogeneous mixture Substances 0.000 description 1
230000036039 immunity Effects 0.000 description 1
CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
230000003993 interaction Effects 0.000 description 1
229960000310 isoleucine Drugs 0.000 description 1
229960003136 leucine Drugs 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
239000012528 membrane Substances 0.000 description 1
229930182817 methionine Natural products 0.000 description 1
GGGDNPWHMNJRFN-UHFFFAOYSA-N metrizoic acid Chemical compound CC(=O)N(C)C1=C(I)C(NC(C)=O)=C(I)C(C(O)=O)=C1I GGGDNPWHMNJRFN-UHFFFAOYSA-N 0.000 description 1
229960004712 metrizoic acid Drugs 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
229940014662 pantothenate Drugs 0.000 description 1
239000011713 pantothenic acid Substances 0.000 description 1
210000005259 peripheral blood Anatomy 0.000 description 1
239000011886 peripheral blood Substances 0.000 description 1
229960003531 phenolsulfonphthalein Drugs 0.000 description 1
108010055896 polyornithine Proteins 0.000 description 1
230000008569 process Effects 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 1
235000019171 pyridoxine hydrochloride Nutrition 0.000 description 1
239000011764 pyridoxine hydrochloride Substances 0.000 description 1
229960002477 riboflavin Drugs 0.000 description 1
235000019192 riboflavin Nutrition 0.000 description 1
239000002151 riboflavin Substances 0.000 description 1
CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
239000013049 sediment Substances 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
239000004474 valine Substances 0.000 description 1
229940088594 vitamin Drugs 0.000 description 1
239000011782 vitamin Substances 0.000 description 1
235000013343 vitamin Nutrition 0.000 description 1
229930003231 vitamin Natural products 0.000 description 1
239000011720 vitamin B Substances 0.000 description 1
235000019156 vitamin B Nutrition 0.000 description 1
229940011671 vitamin b6 Drugs 0.000 description 1

Classifications

- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
- G01N27/26—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variables; by using electrolysis or electrophoresis
- G01N27/416—Systems
- G01N27/447—Systems using electrophoresis
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/806—Electrical property or magnetic property

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Molecular Biology (AREA)
Chemical & Material Sciences (AREA)
Biochemistry (AREA)
Immunology (AREA)
Physics & Mathematics (AREA)
Analytical Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Health & Medical Sciences (AREA)
General Physics & Mathematics (AREA)
Electrochemistry (AREA)
Pathology (AREA)
Investigating Or Analysing Biological Materials (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Peptides Or Proteins (AREA)
Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
Sink And Installation For Waste Water (AREA)
Investigating Or Analyzing Materials By The Use Of Ultrasonic Waves (AREA)

DD78208922A 1977-11-11 1978-11-07 Diagnostisches verfahren DD140503A5 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
DE19772750521 DE2750521A1 (de)	1977-11-11	1977-11-11	Diagnostisches verfahren

Publications (1)

Publication Number	Publication Date
DD140503A5 true DD140503A5 (de)	1980-03-05

Family

ID=6023547

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DD78208922A DD140503A5 (de)	1977-11-11	1978-11-07	Diagnostisches verfahren

Country Status (18)

Country	Link
US (1)	US4212650A (fr)
JP (1)	JPS5475885A (fr)
AT (1)	ATA806078A (fr)
AU (1)	AU4144478A (fr)
BE (1)	BE871977A (fr)
DD (1)	DD140503A5 (fr)
DE (1)	DE2750521A1 (fr)
DK (1)	DK501278A (fr)
ES (1)	ES474810A1 (fr)
FI (1)	FI783425A7 (fr)
FR (1)	FR2408339A1 (fr)
GB (1)	GB2007716B (fr)
IT (1)	IT7829643A0 (fr)
LU (1)	LU80499A1 (fr)
NL (1)	NL7811184A (fr)
NO (1)	NO783783L (fr)
NZ (1)	NZ188867A (fr)
SE (1)	SE7811576L (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS589060A (ja) *	1981-07-09	1983-01-19	Kureha Chem Ind Co Ltd	電気泳動法による細胞の検査方法
JPS60205263A (ja) *	1984-03-30	1985-10-16	Kureha Chem Ind Co Ltd	電気泳動法による細胞の検査方法
USD336766S (en)	1991-02-22	1993-06-29	Horse Trader Ab	Sports shoe
ES2143362B1 (es) *	1997-02-28	2000-12-16	Univ Valencia Politecnica	Aparato y metodo para caracterizar particulas polarizables por dielectroforesis.

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE314227B (fr) *	1964-08-26	1969-09-01	Lkb Produkter Ab
SE316928B (fr) *	1966-11-25	1969-11-03	Kabi Ab
US3607695A (en) *	1969-02-14	1971-09-21	Pfizer & Co C	Hemoglobinopathy controls
US3708402A (en) *	1970-10-19	1973-01-02	Gen Electric	Measurements of particles and molecules
GB1388719A (en) *	1971-09-02	1975-03-26	Hadassah Medical Relief Ass In	Pure t-globulin and its anti-serum
DE2441536C3 (de) *	1974-08-30	1980-09-11	Behringwerke Ag, 3550 Marburg	Diagnostisches Verfahren
IT1055851B (it) *	1974-08-30	1982-01-11	Behringwerke Ag	Particelle indicatirci per diagnosi in vitro
US4043757A (en) *	1975-05-20	1977-08-23	Ortho Pharmaceutical Corporation	Method for detection of human mammary carcinoma
US3984533A (en) *	1975-11-13	1976-10-05	General Electric Company	Electrophoretic method of detecting antigen-antibody reaction
US4011044A (en) *	1976-07-06	1977-03-08	General Electric Company	Use of laser speckle patterns for measurement of electrophoretic mobilities

1977
- 1977-11-11 DE DE19772750521 patent/DE2750521A1/de not_active Withdrawn
1978
- 1978-11-04 ES ES474810A patent/ES474810A1/es not_active Expired
- 1978-11-07 DD DD78208922A patent/DD140503A5/de unknown
- 1978-11-09 FI FI783425A patent/FI783425A7/fi unknown
- 1978-11-09 SE SE7811576A patent/SE7811576L/xx unknown
- 1978-11-09 LU LU80499A patent/LU80499A1/de unknown
- 1978-11-09 NZ NZ188867A patent/NZ188867A/xx unknown
- 1978-11-09 US US05/959,011 patent/US4212650A/en not_active Expired - Lifetime
- 1978-11-09 IT IT7829643A patent/IT7829643A0/it unknown
- 1978-11-09 JP JP13802378A patent/JPS5475885A/ja active Pending
- 1978-11-09 AU AU41444/78A patent/AU4144478A/en active Pending
- 1978-11-10 NL NL7811184A patent/NL7811184A/xx not_active Application Discontinuation
- 1978-11-10 NO NO783783A patent/NO783783L/no unknown
- 1978-11-10 AT AT806078A patent/ATA806078A/de not_active Application Discontinuation
- 1978-11-10 DK DK501278A patent/DK501278A/da unknown
- 1978-11-13 BE BE191700A patent/BE871977A/fr unknown
- 1978-11-13 GB GB7844214A patent/GB2007716B/en not_active Expired
- 1978-11-13 FR FR7831996A patent/FR2408339A1/fr not_active Withdrawn

Also Published As

Publication number	Publication date
GB2007716A (en)	1979-05-23
LU80499A1 (de)	1979-06-15
DK501278A (da)	1979-05-12
NO783783L (no)	1979-05-14
ES474810A1 (es)	1979-03-16
ATA806078A (de)	1981-01-15
SE7811576L (sv)	1979-05-12
FI783425A7 (fi)	1979-05-12
IT7829643A0 (it)	1978-11-09
GB2007716B (en)	1982-04-21
FR2408339A1 (fr)	1979-06-08
NZ188867A (en)	1981-10-19
AU4144478A (en)	1979-05-17
DE2750521A1 (de)	1979-05-17
US4212650A (en)	1980-07-15
NL7811184A (nl)	1979-05-15
BE871977A (fr)	1979-05-14
JPS5475885A (en)	1979-06-18

Publication	Publication Date	Title
Nelson et al.	1985	Characterization of protein F1 (47 kDa, 4.5 pI): a kinase C substrate directly related to neural plasticity
Friou et al.	1958	Identification of the nuclear component of the interaction of lupus erythematosus globulin and nuclei
EP0021152B1 (fr)	1984-02-15	Procédé pour la détermination immunologique d'une matière de membrane basale, fragments de membranes basales spécifiques pour ce procédé et procédé pour leur préparation, resp. leur obtention
DE2608667A1 (de)	1976-09-09	Diagnostisches feststoffreagens und verfahren zu dessen herstellung
DE3152113C2 (de)	1994-06-09	Verfahren zum Bestimmen der Stoffwechselumwandlung bestimmter Chemikalien und Wirkstoffe
EP0008432A1 (fr)	1980-03-05	Procédé de détermination immunologique
DE3209149A1 (de)	1983-10-06	Verfahren zur gemeinsamen immunologischen bestimmung von prokollagen-peptid (typ iii) und prokollagen-peptid col 1 (typ iii) und verfahren zur herstellung von anti-prokollagen-peptid col 1 (typ iii)-serum
DE69001972T2 (de)	1993-09-23	Mittel zum nachweis von gehirnkrankheiten in zusammenhang mit nervenscheidenmarkzerstoerung, insbesondere sklerosis multiplex.
DE3034142C2 (fr)	1990-02-01
EP3438667B1 (fr)	2020-12-30	Essai de liaison pour diagnostiquer la thrombocytopénie induite par l'héparine
DE2728801A1 (de)	1978-05-18	Verfahren zur radio-immunologischen bestimmung von schilddruese stimulierendem hormon und reagenz zur durchfuehrung des verfahrens
DE69711749T2 (de)	2002-11-14	Verfahren zur Vorbereitung eines diagnostischen Reagenz für Hepatitis C Virusinfektion
DE2934757C2 (de)	1984-12-20	Zusammensetzung und Verfahren zur Bestimmung von Humanimmunglobulin-G
DD140503A5 (de)	1980-03-05	Diagnostisches verfahren
Marc et al.	1972	Use of the megathrombocyte to demonstrate thrombopoietin
EP1210109A2 (fr)	2002-06-05	Utilisation d'au moins un inhibiteur d'aminopeptidase
DE69621915T2 (de)	2003-01-23	Anti-dns-antikörpernachweis mittels erkennung und bindung telomerischer dns-sequenzen
DE2023989B2 (de)	1973-09-20	Verfahren zur Herstellung von aus Antigen Tragerstoffgemischen bestehenden und gegebenenfalls Antikörper enthalten den fertigen serodiagnostischen, auf einen Objektträger aufgebrachten lager bestandigen Testsubstanzen
DE3015462A1 (de)	1980-10-30	Verfahren zur bestimmung von interferon und reagens zur durchfuehrung des verfahrens
DE2638250C2 (de)	1985-11-28	Diagnostisches Verfahren zum Bestimmen der Anwesenheit oder Abwesenheit eines spezifischen Proteins in einer biologischen Probe, sowie Vorrichtung zur Durchführung des Verfahrens
DE2441536C3 (de)	1980-09-11	Diagnostisches Verfahren
EP0011716A1 (fr)	1980-06-11	Réactif pour la détermination de mononucléose infectieuse et procédé pour sa préparation
AT389947B (de)	1990-02-26	Verfahren zur bestimmung des aktuellen pegels von cyclosporin-a bzw. des diesem verwandter immunsuppressiva sowie jenes deren biologisch aktiver metaboliten im blut
EP0025508B1 (fr)	1983-08-03	Procédé de préparation de la troisième composante du complément à partir de plasma sanguin humain
EP0253255A2 (fr)	1988-01-20	Procédé et trousse d'essai de détection de monomères de fibrine dans le sang